Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions
This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Subscribe To Our Newsletter & Stay Updated
